19
Participants
Start Date
June 30, 2006
Primary Completion Date
March 31, 2009
Study Completion Date
April 30, 2009
KRN5500
Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo . The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
Placebo
Normal Saline given as dose escalation for placebo
St. Agnes Healthcare, Inc, Baltimore
Carolina Pain Institute, PA, Winston-Salem
Duke University Medical Center, Durham
Keog Pharma, Inc., Jupiter
Hematology and Oncology Specialists, LLC, Covington
Huntsman Cancer Institute, Salt Lake City
Cancer Institute Medical Group, Los Angeles
Ghassan Al-Jazayrly, M.D., Inc., Los Angeles
University of California / Irvine Chao Family Comprehensive Cancer Center, Orange
Massachusetts General Hospital, Boston
East Orange VA Medical Center, East Orange
Dr. Rivera-Colon, Rio Piedras
Lead Sponsor
DARA Therapeutics
INDUSTRY